PMID- 36171097
OWN - NLM
STAT- MEDLINE
DCOM- 20220930
LR  - 20221116
IS  - 1880-9952 (Electronic)
IS  - 1346-4280 (Print)
IS  - 1346-4280 (Linking)
VI  - 62
IP  - 3
DP  - 2022
TI  - Donor-derived diffuse large B-cell lymphoma after haploidentical stem cell 
      transplantation for acute myeloid leukemia.
PG  - 175-180
LID - 10.3960/jslrt.22014 [doi]
AB  - We report a case of donor-derived diffuse large B-cell lymphoma (DLBCL), which 
      developed 5 years after stem cell transplantation from a human leukocyte antigen 
      (HLA)-haploidentical donor for acute myeloid leukemia (AML). A 51-year-old male 
      was diagnosed with AML with variant KMT2A translocation involving 
      t(6;11)(q13;q23). After 12 cycles of azacitidine treatment, fluorescence in situ 
      hybridization (FISH) for KMT2A split signal indicated that 94% of his bone marrow 
      (BM) cells were positive. He underwent peripheral blood stem cell transplantation 
      (PBSCT) from his HLA-haploidentical son. The preconditioning regimen consisted of 
      fludarabine, busulfan, melphalan, and antithymocyte globulin (ATG). The 
      graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus and 
      short-term methotrexate. On day 28, KMT2A FISH analysis indicated that he had 
      achieved a complete response (CR). He continued to receive tacrolimus for the 
      limited type of cutaneous chronic GVHD. Five years after the transplantation, 
      positron emission tomography/computed tomography (PET/CT) showed an abdominal 
      tumor. The tumor was diagnosed as DLBCL without Epstein-Barr virus. BM aspiration 
      revealed the infiltration of lymphoma cells with t(8;14)(q24;q32). Chimerism 
      analysis showed that both the peripheral blood (PB) and abdominal lymphoma cells 
      were of donor origin. After 4 cycles of salvage chemotherapy, PET/CT showed that 
      a CR had been achieved. He underwent a second PBSCT from an HLA-identical 
      unrelated donor. The preconditioning regimen and GVHD prophylaxis were the same 
      as those for the first PBSCT without ATG. The patient's PB revealed complete 
      second donor-type chimerism, and the patient has maintained a CR since the second 
      transplantation.
FAU - Kawashiri, Anna
AU  - Kawashiri A
AD  - Department of Hematology, Toyama Red Cross Hospital, Toyama, Japan.
FAU - Nakagawa, Shun-Ichiro
AU  - Nakagawa SI
AD  - Department of Hematology, Toyama Red Cross Hospital, Toyama, Japan.
FAU - Ishiguro, Chisato
AU  - Ishiguro C
AD  - Department of Hematology, Toyama Red Cross Hospital, Toyama, Japan.
FAU - Mochizuki, Kanako
AU  - Mochizuki K
AD  - Department of Hematology, Toyama Red Cross Hospital, Toyama, Japan.
FAU - Maeda, Yoshinobu
AU  - Maeda Y
AD  - Division of Diagnostic Pathology, Toyama Red Cross Hospital, Toyama, Japan.
FAU - Kurokawa, Toshiro
AU  - Kurokawa T
AD  - Department of Hematology, Toyama Red Cross Hospital, Toyama, Japan.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Japan
TA  - J Clin Exp Hematop
JT  - Journal of clinical and experimental hematopathology : JCEH
JID - 101141257
RN  - 0 (Antilymphocyte Serum)
RN  - 0 (HLA Antigens)
RN  - G1LN9045DK (Busulfan)
RN  - M801H13NRU (Azacitidine)
RN  - Q41OR9510P (Melphalan)
RN  - WM0HAQ4WNM (Tacrolimus)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Antilymphocyte Serum/therapeutic use
MH  - Azacitidine/therapeutic use
MH  - Busulfan/therapeutic use
MH  - *Epstein-Barr Virus Infections
MH  - *Graft vs Host Disease/etiology/prevention & control
MH  - HLA Antigens
MH  - *Hematopoietic Stem Cell Transplantation/methods
MH  - Herpesvirus 4, Human
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Leukemia, Myeloid, Acute/genetics/therapy
MH  - *Lymphoma, Large B-Cell, Diffuse/drug therapy
MH  - Male
MH  - Melphalan/therapeutic use
MH  - Methotrexate/therapeutic use
MH  - Middle Aged
MH  - Positron Emission Tomography Computed Tomography
MH  - Tacrolimus/therapeutic use
MH  - Transplantation Conditioning/methods
PMC - PMC9635034
OTO - NOTNLM
OT  - chronic GVHD
OT  - haploidentical stem cell transplantation
OT  - post-transplantation lymphoproliferative disorder (PTLD)
COIS- CONFLICT OF INTEREST The authors declare that they have no conflicts of interest.
EDAT- 2022/09/29 06:00
MHDA- 2022/10/01 06:00
PMCR- 2022/09/28
CRDT- 2022/09/28 21:41
PHST- 2022/09/28 21:41 [entrez]
PHST- 2022/09/29 06:00 [pubmed]
PHST- 2022/10/01 06:00 [medline]
PHST- 2022/09/28 00:00 [pmc-release]
AID - 22014 [pii]
AID - 10.3960/jslrt.22014 [doi]
PST - ppublish
SO  - J Clin Exp Hematop. 2022;62(3):175-180. doi: 10.3960/jslrt.22014.